Roberts
Executive Summary
Ribogene grants Roberts exclusive marketing rights in North America and Mexico for Ribogene's Emitasol, a Phase III intranasal delivery formulation of metoclopramide used to treat emesis, especially among chemotherapy patients. Ribogene will provide up to $7 mil. for development through Phase III and submission of an NDA. The NDA submission target is the second half of 1999, Roberts says. In a separate transaction, Roberts will purchase $10 mil. of Ribogene convertible preferred stock